Psoriasis-associated vascular disease: the role of HDL

Area of Science:

• Dermatology and Immunology
• Cardiovascular Medicine
• Metabolic Research

Background:

• Psoriasis is a chronic inflammatory disease affecting 2-3% of the population.
• Strong epidemiological links exist between psoriasis, cardiovascular disease (CVD), and atherosclerosis.
• CVD is the leading cause of mortality in severe psoriasis cases, even after accounting for traditional risk factors.

Purpose of the Study:

• To investigate the mechanisms underlying the increased cardiovascular risk in psoriasis patients.
• To explore alterations in lipid metabolism, specifically high-density lipoprotein (HDL) composition and function.
• To assess the impact of biologic therapy on HDL alterations in psoriasis.

Main Methods:

• Analysis of lipid metabolism and HDL parameters in psoriatic patients.
• Evaluation of HDL composition and functional assays.
• Assessment of structural and functional HDL changes following biologic therapy.

Main Results:

• Psoriatic patients exhibit significant alterations in lipid metabolism.
• Key changes observed in HDL composition and function, impacting its atheroprotective role.
• Biologic therapy demonstrated the ability to reverse both structural and functional HDL deficits.

Conclusions:

• Altered HDL function is a significant contributing mechanism to the elevated CVD risk in psoriasis.
• Biologic therapies show promise in ameliorating HDL dysfunction, suggesting a therapeutic avenue for cardiovascular complications in psoriasis.